All In Biotech

Drug Trial Radar · NCT06604767

Study of a Respiratory Syncytial Virus/Human Metapneumovirus/Parainfluenza Virus Type 3 Vaccine Candidate in Adults Aged 60 Years and Older

A Phase 1, Dose-Escalation, Randomized, Active-Controlled, Modified Double-Blind, Parallel-Group, Multi-Arm Study to Investigate the Safety and Immunogenicity of a Combined Respiratory Syncytial Virus/Human Metapneumovirus/Parainfluenza Virus Type 3 Vaccine Candidate in Adult Participants Aged 60 Years and Older

Last checked: Nov 20, 2026Latest source record: Apr 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 390 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

390

Actual

Start

Sep 17, 2024

Primary completion

Mar 24, 2026

Study completion Mar 24, 2026

Sponsor

Lead sponsor
Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
Sponsor type
Industry
First posted
Sep 19, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this phase 1 study is to evaluate whether the vaccine is safe and can help the body to develop germ fighting agents called "antibodies" (immunogenicity) against the respiratory syncytial virus (RSV), human metapneumovirus (hMPV), and parainfluenza virus type 3 (PIV3). The study will use different doses of PIV3 only and different combinations of RSV/hMPV/PIV3 or RSV/hMPV or only RSV vaccine in adults aged 60 years and older.

Conditions

  • Respiratory Syncytial Virus Infection
  • Metapneumovirus Infection
  • Parainfluenzae Virus Infection

Interventions

  • parainfluenza virus type 3 vaccine (PIV3)Biological

    Pharmaceutical form:Frozen liquid solution -Route of administration:Intramuscular

  • RSV/hMPV/PIV3 vaccineBiological

    Pharmaceutical form:Frozen liquid solution-Route of administration:Intramuscular

  • RSV/hMPV vaccineBiological

    Pharmaceutical form:Frozen liquid solution-Route of administration:Intramuscular

  • RSV vaccine 1Biological

    Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular

  • RSV vaccine 2Biological

    Pharmaceutical form:Frozen liquid solution-Route of administration:Intramuscular

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Presence of unsolicited systemic adverse events (AEs) reported in the 30 minutes after each vaccinationTime frame: Within 30 minutes after each vaccination
  2. Presence of solicited administration site reactions within 7 days after vaccinationTime frame: Within 7 days after vaccination
  3. Presence of solicited systemic reactions within 7 days after vaccinationTime frame: Within 7 days after vaccination
  4. Presence of unsolicited AEs within 28 days after vaccinationTime frame: Within 28 days after vaccination
  5. Presence of serious adverse events (SAEs)Time frame: Within 6 months after vaccination
  6. Presence of adverse events of special interest (AESIs)Time frame: Within 6 months after vaccination
  7. Presence of related SAEs throughout the studyTime frame: Throughout the study, approximately 12 months
  8. Presence of related AESIs throughout the studyTime frame: Throughout the study, approximately 12 months
  9. Presence of related fatal SAEs throughout the studyTime frame: Throughout the study, approximately 12 months
  10. Presence of out-of-range biological test results (including shift from baseline values)Time frame: Within 7 days after vaccination

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • Investigational Site Number : 0360006

    Blacktown, New South Wales, Australia

  • Investigational Site Number : 0360001

    Botany, New South Wales, Australia

  • Investigational Site Number : 0360009

    Brookvale, New South Wales, Australia

  • Investigational Site Number : 0360005

    Kanwal, New South Wales, Australia

  • Investigational Site Number : 0360004

    Miranda, New South Wales, Australia

  • Investigational Site Number : 0360008

    Herston, Queensland, Australia

  • Investigational Site Number : 0360003

    Bayswater, Victoria, Australia

  • Investigational Site Number : 0360002

    Camberwell, Victoria, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.